Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Doug this is huge...Dr. Camidge is ESMO presenter...

The article basically states that ALK is not just 4-5% of NSCLC (with ALK+ levels above 15%) but an additional 9.5% (10% of the non-ALK 95%) with ALK levels between 10-15% may also benefit from ALK inhibitors. That's a total of 15%, triple the currently assumed population for ALK inhibitors.

Of course then we could add another 1.5% for the ALK+ patients resistant to Crizotinib demonstrating mutated EGFR (reference the article you posted earlier today), and bring the total to 16.5%, but then we might as well include the 7-8% with T790m (50% of EGFR)for a grand total of 24% of all NSCLC.

Anyone think 300,000 patients per annum will add value?

Let's go ESMO!